Senhwa Biosciences, Inc. (TPEX:6492)
Taiwan · Delayed Price · Currency is TWD 44.00
-0.45 (-1.01%)
Jun 18, 2026, 1:30 PM CST
Senhwa Biosciences Company Description
Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients.
The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma.
It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.
Senhwa Biosciences, Inc.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jason Huang |
Contact Details
Address: No. 225, Peihsin Road New Taipei City, 23143 Taiwan | |
| Phone | 886 2 8911 9856 |
| Website | senhwabio.com |
Stock Details
| Ticker Symbol | 6492 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006492002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason Huang M.D. | Acting Chief Executive Officer and Chief Medical Officer |
| Sarah Chang CPA | Executive Vice President, Chief Financial Officer and Accounting Supervisor |
| Joanne Lo Ph.D. | Acting Chief Operating Officer and Business Development Director |